Research programme: tyrosine kinase inhibitors - AllerganAlternative Names: TKI research programme - Allergan
Latest Information Update: 05 Aug 2015
At a glance
- Originator Allergan
- Class Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration
Most Recent Events
- 28 Feb 2008 Preclinical development is ongoing
- 11 Oct 2004 Preclinical trials in Age-related macular degeneration in USA (unspecified route)